Evaluation of Co-formulated Pembrolizumab/Quavonlimab Versus Other Treatments in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer

Trial Information
Eligibility
Locations

Trial Purpose

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT04895722

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Dates

Actual study start date June 25, 2021
Estimated primary completion date September 28, 2025
Estimated study completion date October 28, 2025

Eligibility

Conditions

Colorectal Cancer

Age Range

18 - No Age Maximum

Sex

All

Trial locations

What Can You Do Next?

If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.

Discuss With Your Doctor

Print this page or email it to your doctor to discuss at your next visit.

CLINICALTRIALS.GOV IDENTIFIER:

NCT04895722

When speaking to your doctor, please have the trial identifier number available.

Participating in a clinical trial is an important decision.

Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.